Icon

NIASPAN (nda020381)- (1GM,375MG,500MG,750MG)

NIACIN ABBVIE
1GM,375MG,500MG,750MG
Yes Yes
2022-Jun-18 Expired
None None
None No
NIASPAN contains extended-release niacin (nicotinic acid), and is indicated: • To reduce elevated TC, LDL-C, Apo B and TG, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. • To reduce the risk of recurrent nonfatal myocardial infarction in patients with a history of myocardial infarction and hyperlipidemia. • In combination with a bile acid binding resin: ◦ Slows progression or promotes regression of atherosclerotic disease in patients with a history of coronary artery disease (CAD) and hyperlipidemia. ◦ As an adjunct to diet to reduce elevated TC and LDL-C in adult patients with primary hyperlipidemia. • To reduce TG in adult patients with severe hypertriglyceridemia.
14 0 10
Total Other Developers 4
Drugs with Suitability No
1GM ** ** - - 6
375MG ** ** - - -
500MG ** ** - - 6
750MG ** ** - - 3
NDA Sales Available Total Generic Sales Available
No 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ********* ** ***** ******* *********** **** **. **-*, ***** *-*, ***** ********** ****, *****, ********, *** ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ****** ****** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** **-**, ****** ** *** ******* ********** ****** ********, *****, ***** ******, ***** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ** ***** ******* *********** **** **. **-*, ***** *-*, ***** ********** ****, *****, ********, *** ******, ***** (***) ***
****** ********* ** ***** ******* *********** **** **. **-*, ***** *-*, ***** ********** ****, *****, ********, *** ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ****** ****** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.